Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
J Hosp Infect ; 148: 138-144, 2024 Mar 28.
Artículo en Inglés | MEDLINE | ID: mdl-38554806

RESUMEN

BACKGROUND: The Radboudumc developed a smartphone application (WondGezond) to collect surgical wound-healing information provided by the patient. AIM: To evaluate usability and outcomes to assess its potential for early surgical site infection (SSI) detection. METHODS: Patients surgically treated for degenerative spinal disorders or carpal tunnel syndrome between August 2020 and February 2023 were enrolled one day post surgery and asked to download the app via a quick-response (QR) code. Participants uploaded a photo and answered four questions about their wound daily, for 14 days. Afterwards, participants indicated whether they received treatment for a suspected SSI (participant-reported outcome). Two neurosurgeons independently assessed photos and questionnaire answers for suspected SSIs (physician-assessed outcome). The association between both outcomes was determined by calculating sensitivity, specificity, and positive and negative predictive value (PPV/NPV). FINDINGS: After 2009 surgeries, 1695 QR-codes were distributed and 412 (21%) were activated. In all, 232 (56%) participants completed the 14-day period of whom 22 (10%) reported SSI treatment. Physician assessment identified 15 (7%) SSIs. Concordance was reached in 88% of cases. Among 27 discordant cases were 17 false-positives and 10 false-negatives, resulting in low sensitivity (33%) and PPV (23%), but high NPV (95%). CONCLUSION: WondGezond provides clinicians with information regarding wound healing and SSIs to follow-up on patients at risk, while possibly also reducing antibiotic (over)treatment and unnecessary visits for patients without issues in wound healing. However, the low participation and false-positive results render the app in its current form unsuitable for surveillance purposes. Further validation of WondGezond is required.

2.
Antimicrob Resist Infect Control ; 10(1): 31, 2021 02 05.
Artículo en Inglés | MEDLINE | ID: mdl-33546759

RESUMEN

BACKGROUND: Central line-associated bloodstream infections (CLABSI) are a main focus of infection prevention and control initiatives in neonatal care. Standardised surveillance of neonatal CLABSI enables intra- and interfacility comparisons which can contribute to quality improvement. To date, there is no national registration system for CLABSI in neonatal care in the Netherlands and several criteria are used for local monitoring of CLABSI incidence rates. To achieve standardised CLABSI surveillance we conducted a consensus procedure with regard to nationwide neonatal CLABSI surveillance criteria (SC). METHODS: A modified Delphi consensus procedure for the development of nationwide neonatal CLABSI SC was performed between January 2016 and January 2017 in the Netherlands. An expert panel was formed by members of the Working Group on Neonatal Infectious Diseases of the Section of Neonatology of the Dutch Paediatric Society. The consensus procedure consisted of three expert panel rounds. RESULTS: The expert panel achieved consensus on Dutch neonatal CLABSI SC. Neonatal CLABSI is defined as a bloodstream infection occurring more than 72 h after birth, associated with an indwelling central venous or arterial line and laboratory confirmed by one or more blood cultures. In addition, the blood culture finding should not be related to an infection at another site and one of the following criteria can be applied: 1. a bacterial or fungal pathogen is identified from one or more blood cultures; 2. the patient has clinical symptoms of sepsis and 2A) a common commensal is identified in two separate blood cultures or 2B) a common commensal is identified by one blood culture and C-reactive protein level is above 10 mg/L in the first 36 h following blood culture collection. CONCLUSIONS: The newly developed Dutch neonatal CLABSI SC are concise, specified to the neonatal population and comply with a single blood culture policy in actual neonatal clinical practice. International agreement upon neonatal CLABSI SC is needed to identify best practices for infection prevention and control.


Asunto(s)
Infecciones Relacionadas con Catéteres/diagnóstico , Cateterismo Venoso Central , Consenso , Técnica Delphi , Humanos , Recién Nacido , Control de Infecciones , Países Bajos , Sepsis/diagnóstico
3.
J Antimicrob Chemother ; 73(9): 2305-2313, 2018 09 01.
Artículo en Inglés | MEDLINE | ID: mdl-29701775

RESUMEN

Objectives: The objectives of this study were to explore inter-study heterogeneity in the pharmacokinetics (PK) of orally administered rifampicin, to derive summary estimates of rifampicin PK parameters at standard dosages and to compare these with summary estimates for higher dosages. Methods: A systematic search was performed for studies of rifampicin PK published in the English language up to May 2017. Data describing the Cmax and AUC were extracted. Meta-analysis provided summary estimates for PK parameter estimates at standard rifampicin dosages. Heterogeneity was assessed by estimation of the I2 statistic and visual inspection of forest plots. Summary AUC estimates at standard and higher dosages were compared graphically and contextualized using preclinical pharmacodynamic (PD) data. Results: Substantial heterogeneity in PK parameters was evident and upheld in meta-regression. Treatment duration had a significant impact on the summary estimates for rifampicin PK parameters, with Cmax 8.98 mg/L (SEM 2.19) after a single dose and 5.79 mg/L (SEM 2.14) at steady-state dosing, and AUC 72.56 mg·h/L (SEM 2.60) and 38.73 mg·h/L (SEM 4.33) after single and steady-state dosing, respectively. Rifampicin dosages of at least 25 mg/kg are required to achieve plasma PK/PD targets defined in preclinical studies. Conclusions: Vast inter-study heterogeneity exists in rifampicin PK parameter estimates. This is not explained by the available modifying variables. The recommended dosage of rifampicin should be increased to improve efficacy. This study provides an important point of reference for understanding rifampicin PK at standard dosages as efforts to explore higher dosing strategies continue in this field.


Asunto(s)
Antibióticos Antituberculosos/administración & dosificación , Antibióticos Antituberculosos/farmacocinética , Voluntarios Sanos , Rifampin/administración & dosificación , Rifampin/farmacocinética , Tuberculosis/tratamiento farmacológico , Administración Oral , Adulto , Femenino , Humanos , Masculino
4.
Epidemiol Infect ; 141(10): 2022-30, 2013 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-23445786

RESUMEN

This paper describes the practical use of social network diagrams in the management of an outbreak of Escherichia coli O157 (VTEC) in a primary school in London. The diagrams were created during the outbreak to establish the extent and nature of person-to-person transmission in the cases and their contacts. The diagrams supported a tailored public health action, and hence aided in the control of the outbreak. We conclude that for selected infectious diseases, social network diagrams can provide a valuable tool in the management of an outbreak.


Asunto(s)
Trazado de Contacto/métodos , Brotes de Enfermedades , Infecciones por Escherichia coli/epidemiología , Escherichia coli O157/aislamiento & purificación , Red Social , Manejo de la Enfermedad , Infecciones por Escherichia coli/transmisión , Humanos , Londres/epidemiología , Instituciones Académicas
5.
Euro Surveill ; 17(13)2012 Mar 29.
Artículo en Inglés | MEDLINE | ID: mdl-22490381

RESUMEN

Diagnoses of Shigella flexneri in the United Kingdom (UK) are usually travel-related. However, since 2009, there has been an overall increase in UK-acquired cases. The Health Protection Agency has been investigating a national outbreak of S. flexneri detected in 2011 and which is still ongoing. Cases occurred mostly in men who have sex with men and were of serotype 3a. The investigation aimed at obtaining epidemiological data to inform targeted outbreak management and control.


Asunto(s)
Brotes de Enfermedades , Disentería Bacilar/epidemiología , Homosexualidad Masculina , Shigella flexneri/aislamiento & purificación , Adulto , Disentería Bacilar/diagnóstico , Electroforesis en Gel de Campo Pulsado , Inglaterra/epidemiología , Humanos , Masculino , Persona de Mediana Edad , Vigilancia de la Población , Factores de Riesgo , Serotipificación , Shigella flexneri/clasificación , Gales/epidemiología
6.
Int J Tuberc Lung Dis ; 14(9): 1147-52, 2010 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-20819260

RESUMEN

SETTING: Vitamin D deficiency is associated with susceptibility to active tuberculosis (TB) in many settings. In vitro studies and studies on human volunteers showed that two of the first-line anti-tuberculosis drugs, isoniazid and rifampicin, reduce 25-hydroxy vitamin D (25[OH]D) concentrations. OBJECTIVE: To study changes in vitamin D status during treatment of Tanzanian hospitalised patients with pulmonary TB (PTB). DESIGN: We compared serum 25[OH]D concentrations in 81 Tanzanian PTB patients before and after 2 months of treatment. RESULTS: Median serum 25[OH]D concentrations increased from 91 nmol/l at baseline to 101 nmol/l after 2 months of TB treatment (median increase 6.0 nmol/l, IQR -0.7-25.0, P = 0.001). Median serum parathyroid hormone concentrations increased from 1.6 to 2.0 pmol/l (median increase 0.46, IQR -0.2-1.1, P < 0.001). CONCLUSION: 25[OH]D serum concentrations increased during the first 2 months of TB treatment in 81 PTB patients in northern Tanzania. Improved dietary intake and increased sunlight exposure may have contributed to the increased 25[OH]D concentrations.


Asunto(s)
Antituberculosos/farmacología , Calcifediol/sangre , Tuberculosis Pulmonar/tratamiento farmacológico , Deficiencia de Vitamina D/complicaciones , Adulto , Femenino , Hospitalización , Humanos , Isoniazida/farmacología , Masculino , Hormona Paratiroidea/sangre , Rifampin/farmacología , Luz Solar , Tanzanía , Tuberculosis Pulmonar/etiología , Vitamina D/administración & dosificación , Vitaminas/administración & dosificación
7.
Trop Med Int Health ; 12(7): 852-5, 2007 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-17596252

RESUMEN

The proportion of patients with antituberculosis drug-induced hepatotoxicity (ATDH) was unexpectedly low during a trial on cotrimoxazole prophylaxis in Malawian HIV-positive pulmonary tuberculosis patients. About 2% of the patients developed grade 2 or 3 hepatotoxicity during tuberculosis (TB) treatment, according to WHO definitions. Data on ATDH in sub-Saharan Africa are limited. Although the numbers are not very strong, our trial and other papers suggest that ATDH is uncommon in this region. These findings are encouraging in that hepatotoxicity may cause less problem than expected, especially in the light of combined HIV/TB treatment, where drug toxicity is a major cause of treatment interruption.


Asunto(s)
Antiinfecciosos/efectos adversos , Antituberculosos/efectos adversos , Enfermedad Hepática Inducida por Sustancias y Drogas , Infecciones por VIH/complicaciones , Tuberculosis Pulmonar/tratamiento farmacológico , Adolescente , Adulto , Distribución por Edad , Antituberculosos/administración & dosificación , Esquema de Medicación , Femenino , Infecciones por VIH/epidemiología , Humanos , Hepatopatías/complicaciones , Hepatopatías/epidemiología , Malaui/epidemiología , Masculino , Persona de Mediana Edad , Distribución por Sexo , Combinación Trimetoprim y Sulfametoxazol/efectos adversos , Tuberculosis Pulmonar/complicaciones , Tuberculosis Pulmonar/epidemiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...